Beneficial Effect of Flecainide Controlled Release on the Quality of Life of Patients with Atrial Fibrillation—the REFLEC-CR Study
- 31 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cardiovascular Drugs and Therapy
- Vol. 34 (3), 383-389
- https://doi.org/10.1007/s10557-020-06971-5
Abstract
Atrial fibrillation (AF) is the most common cardiac arrhythmia with a considerable impact on patients’ quality of life (QoL).Keywords
This publication has 18 references indexed in Scilit:
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEP Europace, 2016
- Epidemiology of atrial fibrillation: European perspectiveClinical Epidemiology, 2014
- Quality of life in patients with atrial fibrillation: how to assess it and how to improve itEP Europace, 2014
- Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF)EP Europace, 2013
- Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060European Heart Journal, 2013
- Paroxysmal atrial fibrillation and health-related quality of life: the importance of keeping scoreEP Europace, 2010
- Validation of a New Simple Scale to Measure Symptoms in Atrial FibrillationCirculation: Arrhythmia and Electrophysiology, 2009
- A novel, simple scale for assessing the symptom severity of atrial fibrillation at the bedside: The CCS-SAF ScaleCanadian Journal of Cardiology, 2006
- Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: Comparison with the standard form and influence of the CYP2D6 polymorphism*Clinical Pharmacology & Therapeutics, 2002
- The RAND-36 measure of health-related quality of lifeAnnals of Medicine, 2001